Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total Other Products Sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
161
Period ended Jun 30, 2026
Change on a year earlier
-20.3%
202 in Q2 2025
History
27 quarters
Since Q4 2019
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total other products sales ($m)
- Total Other Products Sales — U.S. sales ($M)26 · Q2 2026
- Total Other Products Sales — Europe sales ($M)55 · Q2 2026
- Total Other Products Sales — Rest of World sales ($M)80 · Q2 2026
- AmBisome (liposomal amphotericin B — systemic antifungal) ($M)110 · Q2 2026
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M)51 · Q2 2026
- Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M)36 · Q4 2023
- Ranexa (ranolazine — chronic angina, legacy breakout) ($M)5 · Q4 2021
- Zydelig (idelalisib — hematologic oncology, legacy breakout) ($M)12 · Q4 2021
Cite this data
StockData. (2026). Gilead Sciences Total Other Products Sales ($M) ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other_prod_total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.